Hoth Therapeutics
OverviewSuggest Edit
Hoth Therapeutics is a development stage biopharmaceutical company focused on targeted therapeutics for patients suffering from indications such as atopic dermatitis. The Company also develops the BioLexa Platform, a product candidate intended to prevent the symptom-triggering flare-ups before they occur.
| Type | Public | |
| HQ | New York, NY, US | Map |
| Website | hoththerapeutics.com |
Recent NewsAll News
- Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients
- Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease
- Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer Therapeutic
- Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2)
Hoth Therapeutics Office Locations
Hoth Therapeutics has an office in New York
New York, NY, US (HQ)
1 Rockefeller Plaza, 10th Floor
Hoth Therapeutics Financials and Metrics
Hoth Therapeutics Revenue
| USD | |
|---|---|
Net income (Q2, 2020) | (2.5m) |
EBIT (Q2, 2020) | (2.5m) |
Market capitalization (22-Jan-2021) | 36.9m |
Closing stock price (22-Jan-2021) | 2.3 |
Cash (30-Jun-2020) | 4.9m |
Hoth Therapeutics's current market capitalization is $36.9 m.
Annual
Annual
Annual
Quarterly
| USD | Q3, 2017 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|
Net Income | (1.7m) | (1.9m) | (829.4k) | (2.1m) | (3.8m) | (1.8m) | (4.3m) |
Depreciation and Amortization | 916.0 | 302.0 | 608.0 | 916.0 | 305.0 | 610.0 | |
Accounts Payable | 1.5k | (22.2k) | (71.7k) | 65.0k | (117.0k) | 113.7k | (104.5k) |
Cash From Operating Activities | (240.3k) | (1.6m) | (764.0k) | (1.8m) | (3.4m) | (1.6m) | (4.0m) |
Hoth Therapeutics Cybersecurity Score
Hoth Therapeutics Online and Social Media Presence
Hoth Therapeutics's Trends
Hoth Therapeutics News and Updates
December 23, 2020
Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for...
November 03, 2020
Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its therapeutic HT-005 for the treatment of Cutaneous Lupus Erythematosus (CLE), a chronic...
October 20, 2020
Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer Therapeutic
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that through its commercial licensing agreement with the University of Maryland, Baltimore (UMB) the U.S. Patent and Trademark Office (USPTO) has granted U.S....
September 24, 2020
Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2)
NEW YORK, Sept. 24, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced completing testing to examine the ability of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the...
March 19, 2020
Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment, Developed for Cancer Patients Suffering from Erlotinib-Induced Facial Dermatitis and Hair Loss
NEW YORK, March 19, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company' or "Hoth"), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne as well...
February 12, 2020
Hoth Therapeutics Announces Positive Preliminary, Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease
NEW YORK, Feb. 12, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment...
Hoth Therapeutics Blogs
April 30, 2019
HOTH THERAPEUTICS, INC. TO PRESENT AT THE THINKEQUITY CONFERENCE
NEW YORK, April 30, 2019 /PRNewswire/ — Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today annou…
Hoth Therapeutics Frequently Asked Questions
How many employees does Hoth Therapeutics have?
Hoth Therapeutics has 2 employees.
Who are Hoth Therapeutics competitors?
Competitors of Hoth Therapeutics include Alexion Pharmaceuticals, KiOmed Pharma and Veloxis Pharmaceuticals.
Where is Hoth Therapeutics headquarters?
Hoth Therapeutics headquarters is located at 1 Rockefeller Plaza, 10th Floor, New York.
Where are Hoth Therapeutics offices?
Hoth Therapeutics has an office in New York.
How many offices does Hoth Therapeutics have?
Hoth Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies